 Madrigal Pharmaceuticals Inc NASDAQ:MDGL shares have soared more than 250 after the biopharmaceutical company shared positive topline results from its pivotal Phase 3 MAESTRO-NASH biopsy clinical trial of resmetirom, a liver-directed selective thyroid hormone receptor agonist. The company, which is pursuing novel therapeutics for nonalcoholic steatohepatitis NASH, said that resmetirom achieved both primary endpoints and potentially clinically meaningful effects with both daily oral doses 80mg and 100mg relative to placebo in the 52-week serial biopsy trial of more than 950 patients. 